
Brainsway Ltd. BWAY
$ 14.27
1.64%
Quarterly report 2025-Q2
added 05-13-2026
Brainsway Ltd. General and Administrative Expenses 2011-2026 | BWAY
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Brainsway Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.8 M | 5.32 M | 6.85 M | 5.78 M | 3.31 M | 4.39 M | 8.23 M | 7.47 M | 5.74 M | 3.61 M | 2.34 M | 1.43 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.23 M | 1.43 M | 5.02 M |
Quarterly General and Administrative Expenses Brainsway Ltd.
| 2025-Q2 | 2024-Q4 | 2023-Q4 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.18 M | 5.8 M | 5.32 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.8 M | 3.18 M | 4.76 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Enzo Biochem
ENZ
|
21.7 M | - | -8.98 % | $ 14.8 K | ||
|
Centogene N.V.
CNTG
|
46.7 M | - | -6.23 % | $ 30.6 M | ||
|
Heska Corporation
HSKA
|
64.1 M | - | - | $ 1.31 B | ||
|
Fulgent Genetics
FLGT
|
117 M | $ 19.5 | 7.5 % | $ 600 M | ||
|
Celcuity
CELC
|
27.2 M | $ 92.47 | 3.96 % | $ 4.32 B | ||
|
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M | ||
|
Co-Diagnostics
CODX
|
9.06 M | $ 5.76 | 11.41 % | $ 7.66 M | ||
|
Castle Biosciences
CSTL
|
229 M | $ 21.6 | 5.93 % | $ 626 M | ||
|
Aspira Women's Health
AWH
|
7.96 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
21.3 M | - | -61.36 % | $ 2.46 M | ||
|
Guardant Health
GH
|
211 M | $ 133.06 | 4.75 % | $ 16.7 B | ||
|
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
22.3 M | - | - | $ 562 M | ||
|
ICON Public Limited Company
ICLR
|
780 M | $ 152.8 | 6.18 % | $ 12 B | ||
|
CareDx, Inc
CDNA
|
108 M | $ 23.12 | 3.63 % | $ 1.23 B | ||
|
Illumina
ILMN
|
1.09 B | $ 168.06 | -1.68 % | $ 26 B | ||
|
Chembio Diagnostics
CEMI
|
24.3 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
2.37 M | - | - | $ 9.42 M | ||
|
Interpace Biosciences
IDXG
|
9.48 M | $ 1.79 | 2.29 % | $ 7.92 M | ||
|
HTG Molecular Diagnostics
HTGM
|
15.8 M | - | -20.0 % | $ 1.06 M | ||
|
Global Cord Blood Corporation
CO
|
187 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
97.9 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
4.16 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
126 M | - | 0.12 % | $ 80.1 M | ||
|
Mettler-Toledo International
MTD
|
998 M | - | - | $ 24.3 B | ||
|
DermTech
DMTK
|
43.8 M | - | -11.32 % | $ 2.94 M | ||
|
Lantheus Holdings
LNTH
|
275 M | - | - | $ 6.94 B | ||
|
NeoGenomics
NEO
|
273 M | $ 11.31 | 11.54 % | $ 1.45 B | ||
|
Charles River Laboratories International
CRL
|
743 M | $ 185.79 | 3.29 % | $ 9.21 B | ||
|
Natera
NTRA
|
1.18 B | $ 222.1 | 4.84 % | $ 30.4 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
453 M | - | - | $ 10.7 B | ||
|
Medpace Holdings
MEDP
|
198 M | $ 458.69 | 1.75 % | $ 13.2 B | ||
|
Exact Sciences Corporation
EXAS
|
889 M | - | - | $ 19.8 B | ||
|
National Research Corporation
NRC
|
54.8 M | $ 19.75 | 3.73 % | $ 442 M | ||
|
Myriad Genetics
MYGN
|
257 M | $ 4.69 | 6.59 % | $ 434 M | ||
|
Personalis
PSNL
|
53.6 M | $ 12.1 | 12.24 % | $ 1.08 B | ||
|
Koninklijke Philips N.V.
PHG
|
628 M | $ 25.99 | 2.52 % | $ 24.6 B | ||
|
Senseonics Holdings
SENS
|
52.5 M | $ 7.01 | 4.32 % | $ 293 M | ||
|
QIAGEN N.V.
QGEN
|
128 M | - | - | $ 10.6 B | ||
|
Soleno Therapeutics
SLNO
|
132 M | - | - | $ 2.69 B | ||
|
Biomerica
BMRA
|
2.98 M | - | - | $ 4.94 M | ||
|
Laboratory Corporation of America Holdings
LH
|
2.22 B | $ 260.97 | 0.79 % | $ 21.7 B | ||
|
Twist Bioscience Corporation
TWST
|
247 M | - | - | $ 4.42 B | ||
|
Thermo Fisher Scientific
TMO
|
8.73 B | $ 482.03 | 1.7 % | $ 182 B | ||
|
Trinity Biotech plc
TRIB
|
28.8 M | $ 0.68 | -2.4 % | $ 244 M | ||
|
Motus GI Holdings
MOTS
|
6.58 M | - | -34.28 % | $ 263 K | ||
|
Neogen Corporation
NEOG
|
218 M | $ 9.12 | 3.52 % | $ 1.98 B | ||
|
Quest Diagnostics Incorporated
DGX
|
1.97 B | $ 196.12 | 1.27 % | $ 21.8 B | ||
|
Invitae Corporation
NVTA
|
192 M | - | - | $ 21.2 M | ||
|
Waters Corporation
WAT
|
240 M | $ 376.47 | -0.87 % | $ 22.4 B |